News for vTv Therapeutics Inc. (VTVT)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

**media[572530]**

Cash Position: Increased to $36.7 million as of December 31, 2024, from $9.4 million the previous year, primarily due to private placement financing and ATM Of

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protoco

vTv Therapeutics said that the U.S. FDA has lifted the clinical hold on the cadisegliatin clinical program, including late stage trial for oral treatment of type 1 diabetes. Read more here.

North Carolina-based Chimerix, Inc. (CMRX) is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

PR NewswireWESTON, Fla., Dec. 9, 2024 WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focu

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. ( VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small

**media[481348]**

On November 18, 2024, Paul Sekhri, President, Chief Executive Officer, and Executive Chairperson of vTv Therapeutics Inc, purchased 5,000 shares of the company.

vTv Therapeutics ends key license agreement with OnKure

vTv Therapeutics announces Q2 financial results with a GAAP EPS of -$0.81.

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license...

U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday. The Dow traded down 0.04% to 40,571.88 whi...

Shares of Bank of Marin Bancorp BMRC fell sharply during Monday's session after the company reported worse-than-expected quarterly earnings. Bank of Marin repo...

Shares of Pitney Bowes Inc. PBI shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its e-commer...

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the...